Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion session - Breast cancer, metastatic

4172 - Management and outcome of metastatic breast cancer in men in the national multicenter observational ESME program


21 Oct 2018


Poster Discussion session - Breast cancer, metastatic



Tumour Site

Breast Cancer


Junien Sirieix


J. Sirieix1, J. Fraisse2, S. Mathoulin-Pelissier3, M. Leheurteur4, L. Vanlemmens5, C. Jouannaud6, V. Dieras7, C. Levy8, F. Dalenc9, M. Mouret-Reynier10, T. Petit11, B. Coudert12, E. Brain13, B. Pistilli14, J. Ferrero15, A. Gonçalves16, L. Uwer17, S. Gourgou18, J. Frenel19

Author affiliations

  • 1 Medical Oncology, Centre Hospitalier Régional Universitaire de Tours (Pôle Kaplan), 37000 - Tours/FR
  • 2 Biometrics Unit, ICM Regional Cancer Institute of Montpellier, 34090 - Montpellier/FR
  • 3 Bordeaux University, Inserm Cic1401 And Clinical And Epidemiological Research Unit, Institut Bergonié, 33000 - Bordeaux/FR
  • 4 Medical Oncology, Centre Henri Becquerel, 76000 - Rouen/FR
  • 5 Medical Oncology, Centre Oscar Lambret, 59000 - Lille/FR
  • 6 Medical Oncology, Institut Jean Godinot, 51056 - Reims/FR
  • 7 Medical Oncology, Centre Eugene - Marquis, 35042 - Rennes/FR
  • 8 Medical Oncology, Centre Francois Baclesse, 14000 - Caen/FR
  • 9 Medical Oncology, Institut Claudius Regaud – IUCT Oncopôle, 31059 - Toulouse/FR
  • 10 Medical Oncology, Centre Jean Perrin, 63011 - Clermont-Ferrand/FR
  • 11 Medical Oncology, GINECO & Paul Strauss Cancer Center and University of Strasbourg, 67065 - Strasbourg/FR
  • 12 Medical Oncology, Centre Georges-François Leclerc, 21000 - Dijon/FR
  • 13 Medical Oncology, Institut Curie, 75005 - Paris & Saint-Cloud/FR
  • 14 Cancer Medecine, Institut Gustave Roussy, 94800 - Villejuif/FR
  • 15 Medical Oncology, Centre Antoine Lacassagne, 06189 - Nice/FR
  • 16 Medical Oncology, Institute Paoli Calmettes, 13009 - Marseille/FR
  • 17 Medical Oncology, Institut de Cancérologie de Lorraine - Alexis Vautrin, 54519 - Vandoeuvre les Nancy/FR
  • 18 Biometrics Unit, Institut du Cancer de Montpellier, 34298 - Montpellier/FR
  • 19 Medical Oncology, ICO Institut de Cancerologie de l'Ouest - René Gauducheau, 44800 - Saint-Herblain/FR


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4172


Breast Cancer (BC) in men accounts for 1% of all BC. Management is still based largely on BC management in women. Only small and selected retrospective series on metastatic cases have been reported so far. Based on a national database, we aimed at providing a large comprehensive analysis of metastatic BC (MBC) in men.


ESME MBC platform is a French multi-center retrospective real life database using a clinical trial-like methodology to collect data from 18 French Comprehensive Cancer Centers. It includes data from each newly diagnosed MBC patients having initiated at least one treatment between 01/2008 and 12/2014. Cases occurring in men were retrieved and compared to the overall female population (characteristics, Student T-test), and to a population of women matched (1/1) on age, histology, grade, adjuvant treatment and metastasis location, regarding treatment effects and survival.


Of 16 701 evaluable patients, 149 (0.89%) men were identified. Main comparative characteristics are listed below.

Men (n=149) Women (n=16552) p

Mean age (SD) (years)

Median age (range) (years)

68.1y (11.2)

69y (44-90)

60.6y (13.8)

61y (19-99)



Histological Subtypes :

- HR+/HER2-

- Triple Negative

- HER2+

- missing

105 (78.4%)

6 (4.5%)

23 (17.1%)


9815 (65.6%)

2315 (15.4%)

2840 (19%)


p= 0.0019

p= 0.0005



Metastatic de novo 49 (32.9%) 4754 (28.7%) p=0.26

In HR+/HER2- men, 45/105 (42.9%) received frontline hormonal therapy : tamoxifen (20/45), aromatase inhibitor (AI) ± LHRH analogs (18/45), others (7/45). Median PFS was 9.8 months (m) without evidence of statistically difference between HT types. Compared with a matched cohort of women , median PFS was similar : 9.8m versus 13.0m (p=0.8). For HR+/HER2- men receiving front line CT (29/105 (27.6%)), median PFS was 6.9m and was similar to the 6.3m PFS in matched women (HR=1.24, [0.69-2.23]). The overall survival in men was 41.8m versus 34.9m in matched women (p=0.745).


We report on one of the largest series of MBC in men. Compared with women, prognosis and treatment effects look the same. More biological information is needed to improve the customized management of MBC in men.

Clinical trial identification

Editorial Acknowledgement

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.